OncoMatch

OncoMatch/Clinical Trials/NCT07181161

Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer

Is NCT07181161 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including AZD0516 and AZD9574 for metastatic prostate cancer.

Phase 1/2RecruitingAstraZenecaNCT07181161Data as of May 2026

Treatment: AZD0516 · AZD9574The main purpose of this study is to assess the safety and tolerability of AZD0516 as monotherapy and/or in combination with other anti-cancer agents for treatment of metastatic prostate cancer.

Check if I qualify

Extracted eligibility criteria

Cancer type

Prostate Cancer

Disease stage

Metastatic disease required

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Cannot have received: STEAP2 targeting modality

Previous treatment with a STEAP2 targeting modality

Cannot have received: chemotherapeutic agent that inhibits topoisomerase activity or metabolic enzymes

chemotherapeutic agent that inhibits topoisomerase activity or metabolic enzymes

Lab requirements

Blood counts

Adequate organ and marrow function in the absence of blood transfusion or growth factor support (within 21 days prior to the scheduled first dose of study intervention)

Kidney function

Adequate organ and marrow function in the absence of blood transfusion or growth factor support (within 21 days prior to the scheduled first dose of study intervention)

Liver function

Adequate organ and marrow function in the absence of blood transfusion or growth factor support (within 21 days prior to the scheduled first dose of study intervention)

Adequate organ and marrow function in the absence of blood transfusion or growth factor support (within 21 days prior to the scheduled first dose of study intervention)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Research Site · Fayetteville, Arkansas
  • Research Site · Los Angeles, California
  • Research Site · Boston, Massachusetts
  • Research Site · Ann Arbor, Michigan
  • Research Site · Detroit, Michigan

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify